A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris
Status:
Completed
Trial end date:
2016-08-26
Target enrollment:
Participant gender:
Summary
Open-label study will evaluate the safety of an approximate 1.5 mg/kg/day dose of oral
sarecycline in the long-term treatment of participants with moderate to severe facial acne
vulgaris.